Equities research analysts at The Goldman Sachs Group started coverage on shares of Privia Health Group (NASDAQ:PRVA – Get Rating) in a report issued on Friday, The Fly reports. The firm set a "buy" rating and a $32.00 price target on the stock. The Goldman Sachs Group's price objective indicates a potential upside of 15.52% from the company's previous close.

A number of other equities research analysts have also recently commented on PRVA. UBS Group started coverage on Privia Health Group in a research note on Thursday, December 8th. They issued a "buy" rating and a $30.00 price objective for the company. Canaccord Genuity Group dropped their price target on Privia Health Group from $50.00 to $43.00 and set a "buy" rating on the stock in a report on Friday, November 11th. Stifel Nicolaus began coverage on Privia Health Group in a research note on Thursday, December 8th. They issued a "buy" rating and a $28.00 target price on the stock. Canaccord Genuity Group reduced their target price on Privia Health Group from $50.00 to $43.00 in a research report on Friday, November 11th. Finally, BTIG Research cut their price objective on Privia Health Group from $45.00 to $40.00 in a report on Monday, January 9th. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, Privia Health Group presently has an average rating of "Buy" and a consensus target price of $38.93.

Privia Health Group Stock Performance

Shares of NASDAQ:PRVA opened at $27.70 on Friday. The firm has a 50 day simple moving average of $24.08 and a 200 day simple moving average of $31.07. Privia Health Group has a 52 week low of $17.99 and a 52 week high of $44.64. The company has a market cap of $3.17 billion, a PE ratio of -76.94 and a beta of 0.81.

Insider Transactions at Privia Health Group

In related news, Director William M. Sullivan sold 12,115 shares of Privia Health Group stock in a transaction that occurred on Friday, January 6th. The shares were sold at an average price of $21.24, for a total transaction of $257,322.60. Following the transaction, the director now directly owns 5,832,968 shares of the company's stock, valued at $123,892,240.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Privia Health Group news, Director William M. Sullivan sold 18,153 shares of Privia Health Group stock in a transaction on Friday, January 20th. The shares were sold at an average price of $25.36, for a total value of $460,360.08. Following the transaction, the director now directly owns 5,808,777 shares of the company's stock, valued at $147,310,584.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William M. Sullivan sold 12,115 shares of Privia Health Group stock in a transaction on Friday, January 6th. The stock was sold at an average price of $21.24, for a total transaction of $257,322.60. Following the completion of the transaction, the director now directly owns 5,832,968 shares in the company, valued at $123,892,240.32. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,583,757 shares of company stock valued at $81,067,912. 57.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Privia Health Group

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Privia Health Group by 7.1% during the third quarter. Vanguard Group Inc. now owns 4,824,724 shares of the company's stock worth $164,331,000 after buying an additional 321,734 shares during the period. BlackRock Inc. increased its stake in shares of Privia Health Group by 16.8% during the third quarter. BlackRock Inc. now owns 3,283,793 shares of the company's stock worth $111,846,000 after purchasing an additional 471,296 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Privia Health Group by 71.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,780,204 shares of the company's stock valued at $80,960,000 after acquiring an additional 1,162,270 shares in the last quarter. FMR LLC grew its stake in Privia Health Group by 78.5% during the 2nd quarter. FMR LLC now owns 1,456,914 shares of the company's stock valued at $42,425,000 after acquiring an additional 640,492 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in Privia Health Group by 25.0% during the 2nd quarter. Principal Financial Group Inc. now owns 1,314,913 shares of the company's stock valued at $38,290,000 after acquiring an additional 263,289 shares in the last quarter. 66.83% of the stock is owned by hedge funds and other institutional investors.

About Privia Health Group

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Featured Articles

• Get a free copy of the StockNews.com research report on Privia Health Group (PRVA)
• Ford Stock Going Forward After Big Earnings Flop
• Insiders And Institutions Buy Wolverine Worldwide
• Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
• Bright Green Corporation Future May be Getting Brighter
• Microsoft Fast Integrating AI Into Enterprise & Healthcare Suites

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.